Patent · US Active

Immunoconjugates targeting CD46 and methods of use thereof

US11484604B2 · kind B2 · utility

0Cited by
155References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 5, 2021
Grant dateNov 1, 2022
Priority date—
Expiry dateAug 5, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K16/3069
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.